Ohio is currently home to 3325 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
NCT04485260
Recruiting
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 in combination with ruxolitinib.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/05/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Myelofibrosis
Register for Updates
A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
NCT04492488
Recruiting
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/04/2022
Locations: Gabrail Cancer Center Research, Canton, Ohio
Conditions: Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
NCT05205070
Recruiting
Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2022
Locations: Site 10-102, Bexley, Ohio
Conditions: Alopecia Areata
Register for Updates
Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
NCT03911076
Recruiting
To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6
Gender:
Female
Ages:
Between 25 years and 70 years
Trial Updated:
04/19/2022
Locations: Obstetrics & Gynecology Associates, Inc., Fairfield, Ohio
Conditions: ASC-US, ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-Epithelial Lesion, LSIL
Register for Updates
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT05116813
Recruiting
This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
04/18/2022
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
NCT02512497
Recruiting
The goal of this clinical research study is to learn if giving romidepsin before and after a stem cell transplant in combination with fludarabine and busulfan can help to control leukemia or lymphoma. Researchers also want to learn the highest tolerable dose of romidepsin that can be given with this combination. The safety of this combination and the safety of giving romidepsin after a stem cell transplant will also be studied. This is an investigational study. Romidepsin is FDA approved and c... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/18/2022
Locations: The Ohio State University Cancer Center, Columbus, Ohio
Conditions: Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma
Register for Updates
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
NCT04548583
Recruiting
Crohn's disease has several phenotypes (inflammatory, stricturing, fistulizing) and location (small bowel, ileocecal, colon, and perianal). Approximately one third of patients have inflammation limited to the colon. Up to two thirds will become medically refractory and require a total abdominal colectomy for symptom control. The purpose of this study is to determine the safety and efficacy of using allogeneic bone marrow derived mesenchymal stem cells (MSCs) delivered by targeted endoscopic deli... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Crohn Colitis
Register for Updates
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
NCT04543994
Recruiting
The purpose of this study is to determine the safety and efficacy of using remestemcel-L, an ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product (MSCs) delivered by targeted endoscopic delivery to treat people for medically refractory ulcerative colitis. This study will enroll adult patients with medically refractory ulcerative colitis who are planning to switch biologic therapy or undergo colectomy as the next stage in their treatment plan.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Ulcerative Colitis
Register for Updates
Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease
NCT05075811
Recruiting
The purpose of this study is to determine the safety and feasibility of using Ossium vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC) to treat people with an ileal pouch anal anastomosis (IPAA) who develop a fistula in the setting of Crohn's disease of the pouch.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Pouch, Ileal, Fistula
Register for Updates
Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease
NCT04791878
Recruiting
This study plans to enroll 10 patients aged 13-17 years of age with refractory perianal fistulizing disease. Patients will be treated by direct injection to the fistula tract(s) with 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Perianal Fistula Due to Crohn's Disease (Disorder)
Register for Updates
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
NCT04578392
Recruiting
Study description - Patients will be randomized according to post-operative recurrence risk to either a high ligation of ileocolic artery or mesenteric sparing ileocolic resection for terminal ileal Crohn's disease. The primary endpoint 6-month endoscopic recurrence. Endpoints - Primary endpoint; 6 months Secondary endpoints at 1 and 5 years post ileocecal resection Study population - Adult Crohn's disease patients with medically refractory terminal ileal Crohn's disease undergoing a primary i... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Crohn Disease
Register for Updates
Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease
NCT04519671
Recruiting
The purpose of this study is to determine the safety and efficacy of using adult allogeneic bone marrow derived mesenchymal stem cells (MSCs), to treat people for medically refractory perianal fistulizing Crohn's disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Perianal Crohn Disease, Perianal Fistula, Crohn Disease
Register for Updates